CAR-T cell therapy
Jun 10, 2025
Bispecific and Trispecific Antibodies: Are They Better Than CAR-Ts?
CAR-T cell therapy has revolutionized the treatment of blood cancers, earning regulatory approval and delivering impressive results in hematologic malignancies. However, its success has not yet translated to solid tumors, where it continues to face significant challenges and limited long-term efficacy. As a result,...
Read More...
Oct 21, 2024
Exosomes: Tiny Messengers with Big Potential in Medical Science
Exosomes are tiny, powerful messengers that are revolutionizing the way we think about communication between cells. These nanosized vesicles carry crucial signals—proteins, lipids, and RNA—between cells, playing a pivotal role in everything from immune responses to tissue repair. What makes exosomes truly exciting ...
Read More...
May 07, 2024
Boehringer Ingelheim’s Diabetic Macular Ischemia Study; Novartis’ Mariana Oncology Acquisition; Astellas and Poseida Therapeutics Partnership; Prime Medicine’s PM359 IND; Pfizer’s TIVDAK FDA Approval
Boehringer Ingelheim Announces Promising Findings From Groundbreaking Study on Diabetic Macular Ischemia Boehringer Ingelheim released encouraging results from the HORNBILL Phase I/IIa trial of BI 764524, marking the pioneering investigation into a potential therapy for individuals with diabetic macular is...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
